Pioneering RNAi Therapeutics for Unmet Needs
Sirnaomics (sirnaomics.com) scores 66 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 14th percentile of 19690 Healthcare brands.
Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company headquartered in Gaithersburg, United States, with operations in both China and the U.S. The company discovers and develops RNAi and mRNA-based drugs, including therapeutics and vaccines, targeting oncology, cardiovascular, metabolic, and aesthetic medicine indications. It utilizes proprietary drug delivery platforms, including PNP and GalAHead™, to address extra-hepatic RNAi delivery challenges. Sirnaomics reports achieving positive Phase IIb clinical outcomes in oncology, marking a notable milestone in its RNA therapeutics pipeline.
| Brand Name | Sirnaomics |
|---|---|
| Domain | sirnaomics.com |
| Industry | Healthcare |
| Headquarters | Gaithersburg |
| Main Competitors | Alnylam Pharmaceuticals (87/100), Arrowhead Pharmaceuticals (78/100), Silence Therapeutics (77/100), Arbutus Biopharma (80/100), Dicerna Pharmaceuticals (76/100), Moderna (94/100), BioNTech (76/100) |
Moz Domain Authority 31/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Sirnaomics is the first to achieve positive Phase IIb clinical outcomes in oncology clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China a…" (Meta description: 74 words. No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt mentions GPTBot, ChatGPT-User, ClaudeBot, Google-Extended, PerplexityBot - all allowed - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on Instagram, YouTube; no detected presence on LinkedIn, X (Twitter), Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Sirnaomics?", Claude could identify the brand as of September 2026. Sirnaomics is a biopharmaceutical company focused on developing therapeutics based on RNA interference (RNAi), particularly siRNA, targeting diseases like cancer, fibrosis, and inflammatory conditions. Best known for Developing siRNA-based therapeutics, including its proprietary polypeptide nanoparticle delivery platform for RNAi drugs.
When asked "Best brands similar to Sirnaomics?", Claude would recommend Sirnaomics as of September 2026. It's a notable player in the RNAi therapeutics space with a distinctive delivery technology, so it would be relevant to mention alongside other RNAi-focused biotech companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Sirnaomics's main competitors in Healthcare: Alnylam Pharmaceuticals (87/100), Arrowhead Pharmaceuticals (78/100), Silence Therapeutics (77/100), Arbutus Biopharma (80/100), Dicerna Pharmaceuticals (76/100).
Sources: Brand Analyzer scan
Sirnaomics offers RNAi and mRNA-based therapeutics and vaccines targeting oncology, cardiovascular, metabolic, and aesthetic medicine conditions. These products are developed using proprietary delivery platforms, including PNP and GalAHead™, designed to enable effective extra-hepatic RNAi delivery.
Sources: Sirnaomics official site
Sirnaomics is a clinical-stage biopharmaceutical company focused on RNA therapeutics, headquartered in Gaithersburg, United States, with a strong presence in both China and the U.S. It specializes in discovering and developing RNAi and mRNA-based drugs for diseases with significant unmet medical needs.
Sources: Sirnaomics official site
Sirnaomics has limited AI-search visibility, scoring 30/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 29, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Sirnaomics official site
Sirnaomics is headquartered in Gaithersburg. Sirnaomics operates in the Healthcare category.
Sources: Wikidata
Sirnaomics discovers and develops RNAi and mRNA-based therapeutics and vaccines, using proprietary drug delivery platforms such as PNP and GalAHead™ to overcome extra-hepatic delivery challenges. Its pipeline targets oncology, cardiovascular, metabolic, and aesthetic medicine indications.
Sources: Sirnaomics official site
Sirnaomics scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Sirnaomics official site
Sirnaomics is known for being the first company to achieve positive Phase IIb clinical outcomes in oncology using RNA therapeutics, and for its proprietary delivery technologies, including the PNP and GalAHead™ platforms, which address extra-hepatic RNAi delivery challenges.
Sources: Sirnaomics official site
Sirnaomics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Sirnaomics official site
Sirnaomics' therapeutics and vaccines are intended for patients with oncology, cardiovascular, metabolic, and other conditions with significant unmet medical needs. Its work also engages healthcare providers and biopharmaceutical partners interested in RNAi and mRNA-based drug development and delivery technologies.
Sources: Sirnaomics official site
Sirnaomics has gained attention in the biopharmaceutical industry for being the first to report positive Phase IIb clinical outcomes in oncology using RNA therapeutics, as well as for its proprietary drug delivery platforms, PNP and GalAHead™, which aim to solve extra-hepatic RNAi delivery challenges.
Sources: Sirnaomics official site
Sirnaomics scores 30/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Sirnaomics has a weak AI-visibility profile at 30/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 31/100 and thin schema.org structured data. In a live check, Claude could already identify Sirnaomics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Sirnaomics: Simple HealthKit (66/100), SimBioSys (66/100), Smirta (66/100), Smokiez CBD (66/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.